Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors
Abstract
This study shows how phage display technology can be applied successfully to in vivo models and can advance molecular oncology through the identification of tumor-homing peptides and their target receptors. Treatment options are still limited for prostate cancer patients who have progressed to develop castrate-resistant osteoblastic bone metastases. The peptides identified in this study may lead to breakthroughs in fighting metastatic androgen-independent prostate cancer by enabling drug targeting and nanotechnology-based therapeutic strategies and may lead to significant advances in the management and therapy of this frequently lethal disease.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 11, 2015
- Source ID
- 10.1073/pnas.1500128112
Entities
People
- Andrey S. Dobroff
- Anna Cecilia Rietz
- Bettina Proneth
- Christopher J. Logothetis
- Jami Mandelin
- Marina Cardo-vila
- Nora M. Navone
- Paul Mathew
- Renata Pasqualini
- Richard L. Sidman
- Sue-hwa Lin
- Wadih Arap
- Wouter H. P. Driessen
Organizations
- Harvard Medical School
- United States Department of Defense
- University of New Mexico
- University of New Mexico School of Medicine
- University of Texas at Austin